Needham Reiterates Buy on G1 Therapeutics, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on G1 Therapeutics (NASDAQ:GTHX) and maintained a $14 price target for the company's stock.

December 06, 2023 | 10:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on G1 Therapeutics and maintained a $14 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating by a reputable analyst such as Gil Blum from Needham typically instills confidence in investors and can lead to a positive short term impact on the stock price. The maintenance of a $14 price target suggests that the analyst sees potential for the stock to rise to that level, which is a bullish signal for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100